134 related articles for article (PubMed ID: 37615040)
1. Looking for
Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
[TBL] [Abstract][Full Text] [Related]
2.
Crémet L; Joffraud L; Eschapasse E; Bihouée T; Tissot A; Gibaud S; Persyn E
Microb Drug Resist; 2022 Aug; 28(8):877-881. PubMed ID: 35763306
[TBL] [Abstract][Full Text] [Related]
3. Synergistic combination of aztreonam and ceftazidime/avibactam against resistant Stenotrophomonas maltophilia on pancreatitis.
De Almeida Torres N; Morales Junior R; Bueno Lopes LF; Zeigler R; Everson Uip D
J Infect Dev Ctries; 2023 Jun; 17(6):881-885. PubMed ID: 37406060
[TBL] [Abstract][Full Text] [Related]
4. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
[TBL] [Abstract][Full Text] [Related]
5. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
6. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia.
Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733
[TBL] [Abstract][Full Text] [Related]
7. Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone.
Moriceau C; Eveillard M; Lemarié C; Chenouard R; Pailhoriès H; Kempf M
Med Mal Infect; 2020 May; 50(3):305-307. PubMed ID: 32014291
[TBL] [Abstract][Full Text] [Related]
8. Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam.
Mojica MF; Papp-Wallace KM; Taracila MA; Barnes MD; Rutter JD; Jacobs MR; LiPuma JJ; Walsh TJ; Vila AJ; Bonomo RA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784669
[No Abstract] [Full Text] [Related]
9. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.
Méndez-Sotelo BJ; Delgado-Beltrán M; Hernández-Durán M; Colín-Castro CA; Esquivel-Bautista J; Ortega-Oliva SA; Ortiz-Álvarez J; García-Contreras R; Franco-Cendejas R; Lopez Jacome LE
PLoS One; 2024; 19(4):e0298577. PubMed ID: 38635685
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
[TBL] [Abstract][Full Text] [Related]
12. Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.
Mojica MF; Rutter JD; Taracila M; Abriata LA; Fouts DE; Papp-Wallace KM; Walsh TJ; LiPuma JJ; Vila AJ; Bonomo RA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266860
[No Abstract] [Full Text] [Related]
13. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test.
Harris H; Tao L; Jacobs EB; Bergman Y; Adebayo A; Tekle T; Lewis S; Dahlquist A; Abbey TC; Wenzler E; Humphries R; Simner PJ
J Clin Microbiol; 2023 May; 61(5):e0164722. PubMed ID: 37070979
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
Wei C; Ni W; Cai X; Zhao J; Cui J
PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Sader HS; Duncan LR; Arends SJR; Carvalhaes CG; Castanheira M
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900683
[TBL] [Abstract][Full Text] [Related]
18. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope.
Avery LM; Nicolau DP
Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
20. In vitro effectiveness of ceftazidime-avibactam in combination with aztreonam on carbapenemase-producing Enterobacterales.
Romina PE; Lucía A; Leticia C; Federica F; Pablo Á; Verónica S; Antonio G; Inés B; Rafael V
J Glob Antimicrob Resist; 2023 Dec; 35():62-66. PubMed ID: 37611893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
